Literature DB >> 25751670

Recent developments in clinical trial designs for HIV vaccine research.

Laura Richert1, Edouard Lhomme, Catherine Fagard, Yves Lévy, Geneviève Chêne, Rodolphe Thiébaut.   

Abstract

HIV vaccine strategies are expected to be a crucial component for controlling the HIV epidemic. Despite the large spectrum of potential candidate vaccines for both prophylactic and therapeutic use, the overall development process of an efficacious HIV vaccine strategy is lengthy. The design of clinical trials and the progression of a candidate strategy through the different clinical development stages remain methodologically challenging, mainly due to the lack of validated correlates of protection. In this review, we describe recent advances in clinical trial designs to increase the efficiency of the clinical development of candidate HIV vaccine strategies. The methodological aspects of the designs for early- (phase I and II) and later -stage (phase IIB and III) development are discussed, taking into account the specificities of both prophylactic and therapeutic HIV vaccine development.

Keywords:  AIDS vaccines; Ad5; Adenovirus 5; DNA, deoxyribonucleic acid; HIV; IDU; IFN-γ; MSM; PrEP; RNA; clinical trials; epidemiologic research design; human immunodeficiency virus; interferon-gamma; intravenous drug users; men having sex with men; pre-exposure prophylaxis; prevention; ribonucleic acid; therapeutic use; treatment outcome

Mesh:

Substances:

Year:  2015        PMID: 25751670      PMCID: PMC4514416          DOI: 10.1080/21645515.2015.1011974

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  57 in total

1.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

2.  In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities.

Authors:  Holly Janes; Peter Gilbert; Susan Buchbinder; James Kublin; Magdalena E Sobieszczyk; Scott M Hammer
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-25       Impact factor: 2.205

3.  Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.

Authors:  Yves Lévy; Rodolphe Thiébaut; Monica Montes; Christine Lacabaratz; Louis Sloan; Bryan King; Sophie Pérusat; Carson Harrod; Amanda Cobb; Lee K Roberts; Mathieu Surenaud; Céline Boucherie; Sandra Zurawski; Constance Delaugerre; Laura Richert; Geneviève Chêne; Jacques Banchereau; Karolina Palucka
Journal:  Eur J Immunol       Date:  2014-09       Impact factor: 5.532

4.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

5.  HIV-1 vaccines and adaptive trial designs.

Authors:  Lawrence Corey; Gary J Nabel; Carl Dieffenbach; Peter Gilbert; Barton F Haynes; Margaret Johnston; James Kublin; H Clifford Lane; Giuseppe Pantaleo; Louis J Picker; Anthony S Fauci
Journal:  Sci Transl Med       Date:  2011-04-20       Impact factor: 17.956

6.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Authors:  Merlin L Robb; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Patricia Morgan; Michael Benenson; Robert M Paris; Joseph Chiu; Elizabeth Adams; Donald Francis; Sanjay Gurunathan; Jim Tartaglia; Peter Gilbert; Don Stablein; Nelson L Michael; Jerome H Kim
Journal:  Lancet Infect Dis       Date:  2012-05-30       Impact factor: 25.071

7.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

8.  Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials.

Authors:  Peter B Gilbert; Alicia Sato; Xiao Sun; Devan V Mehrotra
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

Review 9.  AIDS vaccines and preexposure prophylaxis: is synergy possible?

Authors:  Jean-Louis Excler; Wasima Rida; Frances Priddy; Jill Gilmour; Adrian B McDermott; Anatoli Kamali; Omu Anzala; Gaudensia Mutua; Eduard J Sanders; Wayne Koff; Seth Berkley; Patricia Fast
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-16       Impact factor: 2.205

10.  Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.

Authors:  Laura Richert; Adélaïde Doussau; Jean-Daniel Lelièvre; Vincent Arnold; Véronique Rieux; Amel Bouakane; Yves Lévy; Geneviève Chêne; Rodolphe Thiébaut
Journal:  Trials       Date:  2014-02-26       Impact factor: 2.279

View more
  3 in total

1.  A Bayesian design for phase I cancer therapeutic vaccine trials.

Authors:  Chenguang Wang; Gary L Rosner; Richard B S Roden
Journal:  Stat Med       Date:  2018-10-25       Impact factor: 2.373

Review 2.  Adenoviral vector-based strategies against infectious disease and cancer.

Authors:  Chao Zhang; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

3.  Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.

Authors:  Edouard Lhomme; Laura Richert; Zoe Moodie; Chloé Pasin; Spyros A Kalams; Cecilia Morgan; Steve Self; Stephen C De Rosa; Rodolphe Thiébaut
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.